XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Contract Balances from Contracts with Customers - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Feb. 28, 2023
Dec. 31, 2022
Feb. 28, 2022
Dec. 31, 2021
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
Contract with customer liability $ 47,499 $ 70,111   $ 50,211   $ 92,068
Revenue from contract with customer 49,869 38,078        
Revenue recognized, previously deferred 2,712 25,760        
Current portion of deferred revenue 13,444     $ 13,856    
License and milestone fees            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
Revenue from contract with customer 15,031 30,892        
Future Technological Improvements            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
Revenue recognized, previously deferred   100        
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd | License and milestone fees            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
License agreement upfront payment receivable           45,000
Revenue recognized, previously deferred   21,600        
Current portion of deferred revenue           $ 28,500
Lilly            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
License agreement upfront payment receivable         $ 13,000  
Lilly | License and milestone fees            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
Revenue from contract with customer   9,200        
Lilly | Upfront payment            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
Contract with customer liability   13,000        
KADCYLA | Royalty revenue            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
Net proceeds from sale of residual rights to receive royalty payments 2,700          
Revenue recognized, previously deferred   $ 4,100        
Vertex | License and milestone fees            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
Revenue from contract with customer 15,000          
Vertex | Upfront payment            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]            
License agreement upfront payment receivable     $ 15,000      
Revenue from contract with customer $ 15,000